Analysts' ratings for AbbVie ABBV over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 9 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 4 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 3 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $194.2, with a high estimate of $214.00 and a low estimate of $180.00. Marking an increase of 1.15%, the current average surpasses the previous average price target of $192.00.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of AbbVie among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Evan David Seigerman | BMO Capital | Raises | Outperform | $214.00 | $180.00 |
| Terence Flynn | Morgan Stanley | Raises | Overweight | $196.00 | $191.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $200.00 | $200.00 |
| Christopher Raymond | Piper Sandler | Maintains | Overweight | $190.00 | $190.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $200.00 | $200.00 |
| Christopher Raymond | Piper Sandler | Raises | Overweight | $190.00 | $185.00 |
| Rajesh Kumar | HSBC | Announces | Buy | $185.00 | - |
| Louise Chen | Cantor Fitzgerald | Announces | Overweight | $200.00 | - |
| Carter Gould | Barclays | Lowers | Overweight | $187.00 | $195.00 |
| Evan David Seigerman | BMO Capital | Lowers | Outperform | $180.00 | $195.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AbbVie. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of AbbVie compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of AbbVie's stock. This analysis reveals shifts in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AbbVie's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on AbbVie analyst ratings.
Delving into AbbVie's Background
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
AbbVie: A Financial Overview
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, AbbVie showcased positive performance, achieving a revenue growth rate of 0.7% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: AbbVie's net margin excels beyond industry benchmarks, reaching 11.04%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): AbbVie's ROE stands out, surpassing industry averages. With an impressive ROE of 14.8%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): AbbVie's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: AbbVie's debt-to-equity ratio stands notably higher than the industry average, reaching 9.24. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
How Are Analyst Ratings Determined?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
